Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

Researchers examined the performance of Kd vs Vd for patients with relapsed / refractory multiple myeloma.
Researchers examined the performance of Kd vs Vd for patients with relapsed / refractory multiple myeloma.

Carfilzomib in combination with dexamethasone (Kd) is superior to bortezomib plus dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma regardless of cytogenetic risk, according to a study published in the journal Leukemia.1

The phase 3 ENDEAVOR trial (ClinicalTrials.gov Identifier: NCT01568866) demonstrated that carfilzomib plus dexamethasone significantly reduced the risk of progression or death by 47% compared with bortezomib plus dexamethasone in patients with relapsed or refractory multiple myeloma (hazard ratio [HR], 0.53; 95% CI, 0.44-0.65; P < .0001).

In a preplanned subgroup analysis, researchers evaluated efficacy of carfilzomib plus dexamethasone vs bortezomib plus dexamethasone by cytogenetic risk. Of the 785 patients with known cytogenetics in ENDEAVOR, 27% and 73% had high-risk and standard-risk cytogenetics, respectively.

Among patients with high-risk cytogenetics, treatment with carfilzomib was associated with a 35% reduced risk of progression or death compared with bortezomib (HR, 0.65; 95% CI, 0.45-0.92; P =.0075). Median progression-free survival was 8.8 months with the carfilzomib regimen and 6.0 months with bortezomib.

In the standard-risk group, carfilzomib plus dexamethasone significantly reduced the risk of progression or death by 56% vs bortezomib plus dexamethasone (HR, 0.44; 95% CI, 0.33-0.58; P <.0001); median progression-free survival was not estimable and 10.2 months, respectively.

Investigators also found that 72.2% of carfilzomib-treated patients with high-risk cytogenetics achieved an overall response compared with 58.4% of bortezomib-treated patients in the high-risk group. Similarly, 79.2% of those with standard-risk cytogenetics given carfilzomib vs 66.0% of those in the bortezomib group had a response.

Researchers observed complete responses or better in 15.5% of patients with high-risk cytogenetics and 13.0% of those with standard-risk cytogenetics who received carfilzomib. Only 4.4% of high-risk patients and 7.9% of standard-risk patients treated with bortezomib achieved a complete response or better.

Reference

1. Chng WJ, Goldschmidt H, Dimopoulos MA, et al. Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Feb 3. doi: 10.1038/leu.2016.390 [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs